AUTL - Company ID 0001730463
The table below shows Autolus Therapeutics plc's income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $75.39M | $10.12M | $1.70M | - | - | - |
| Cost of revenue | $96.37M | $11.39M | $0.00 | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $117.69M | $138.44M | $130.48M | $117.35M | $110.84M | $134.89M |
| SG&A |
Autolus Therapeutics plc reported annual revenue of $75.39M for fiscal year 2025. That is up 644.9% from $10.12M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $1.21M (FY 2016) to $75.39M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $131.87M |
| $101.72M |
| $46.74M |
| $31.90M |
| $31.86M |
| $34.97M |
| Operating income | -$270.54M | -$241.43M | -$179.70M | -$143.41M | -$141.05M | -$168.15M |
| Income tax | $1.97M | $1.53M | -$19.00K | $272.00K | $58.00K | -$24.16M |
| Net income | -$287.53M | -$220.66M | -$208.38M | -$148.84M | -$142.10M | -$142.09M |
| EPS (diluted) | -$1.08 | -$0.86 | -$1.20 | -$1.57 | -$1.97 | -$2.76 |